



Docket No.: 262507US0PCT



COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

ATTORNEYS AT LAW

RE: Application Serial No.: 10/517,310

Applicants: Hidehito KOTANI, et al.

Filing Date: December 17, 2004

For: METHOD FOR PREDICTING A DRUG TRANSPORT
CAPABILITY BY ABCG2 POLYMORPHISMS

Group Art Unit: 1634

Examiner: SHAW, AMANDA MARIE

SIR:

Attached hereto for filing are the following papers:


Response to Restriction and Election of species Requirement

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon


Paul J. Killios

Registration No. 58,014

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



RECEIVED
U.S. PATENT & TRADEMARK OFFICE
OCT 05 2006
14248
S 262507US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
HIDEHITO KOTANI, ET AL. : EXAMINER: SHAW, AMANDA MARIE
SERIAL NO: 10/517,310 :
FILED: DECEMBER 17, 2004 : GROUP ART UNIT: 1634
FOR: METHOD FOR PREDICTING A :
DRUG TRANSPORT CAPABILITY BY :
ABCG2 POLYMORPHISMS

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the restriction/election of a single disclosed species requirement mailed September 5, 2006, Applicants provisionally elect with traverse Group I, Claims 1-4, 8, 20 and 21 and for a single species, nucleotide polymorphism at position 421 of SEQ. ID NO:1

Remarks/Arguments begin on page 2 of this paper.